PHARMACYCLICS INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2009-12-08: Form 8-K; Period of report 2009-12-06; Description 8.01 Other Events; Details 8.01.
- 2009-12-07: Form 8-K; Period of report 2009-12-04; Description 8.01 Other Events; Details 8.01.
- 2009-11-12: Form 8-K; Period of report 2009-11-12; Description 8.01 Other Events; Details 8.01.
- 2009-11-02: Form 8-K; Period of report 2009-10-29; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2009-12-08 | 8-K | 2009-12-06 | 8.01 Other Events | 8.01 On December 6, 2009, Pharmacyclics, Inc. (the “Company”) announced interim results from a Phase I/II study showing safety and clinical activity in patients with relapsed / recurrent non-Hodgkin’s Lymphoma (NHL) treated with its HDAC inhibitor PCI-24781 as a single agent. | form8k07380_12062009.htm |
| 2009-12-07 | 8-K | 2009-12-04 | 8.01 Other Events | 8.01 On December 3, 2009, Pharmacyclics, Inc. a Delaware corporation (the "Registrant"), announced that it will host a webcast and conference call on, Tuesday, December 8, 2009 at 11:00am Eastern Time (10:00am Central Time and 8:00am Pacific Time) to discuss clinical data regarding its HDAC Program (PCI-24781) and its BTK Program (PCI-32765) that will be presented at the American Society of Hematology (ASH) meeting. | form8k07380_12042009.htm |
| 2009-11-12 | 8-K | 2009-11-12 | 8.01 Other Events | 8.01 On November 12, 2009, Pharmacyclics, Inc. a Delaware corporation (the "Registrant"), announced that posters related to PCI-24781 and PCI 32765 have been selected for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH), December 5-8, 2009 in New Orleans, Louisiana. | form8k07380_11122009.htm |
| 2009-11-02 | 8-K | 2009-10-29 | 2.02 Results of Operations and Financial Condition | 2.02 On October 29, 2009, Pharmacyclics, Inc., a Delaware corporation (the “Registrant”), issued a press release regarding its financial results for its first quarter of fiscal 2010. | form8k07380_10292009.htm |
| 2009-09-17 | 8-K | 2009-09-17 | 2.02 Results of Operations and Financial Condition | 2.02 On September 17, 2009, Pharmacyclics, Inc., a Delaware corporation (the "Registrant"), issued a press release regarding its financial results for its fiscal quarter and year ended June 30, 2009. | form8k07380_09172009.htm |
| 2009-08-06 | 8-K | 2009-08-05 | 8.01 Other Events | 8.01 On August 5, 2009, Pharmacyclics, Inc. (“Pharmacyclics” or the “Company”) announced the preliminary results of its rights offering to purchase up to 22,500,000 shares of the Company's common stock at a subscription price of $1.28 per share, which expired as of 5:00 p.m., EDT, on July 31, 2009. | form8k07380_08052009.htm |
| 2009-07-24 | 8-K | 2009-07-24 | 8.01 Other Events | 8.01 On July 24, 2009, Pharmacyclics, Inc. (“Pharmacyclics” or the “Company”) has released the information attached hereto as Exhibit 99.1, which provides a presentation about the company, its business, its operations, its finances and recent developments, including the Company’s announced rights offering. | form8k07380_07242009.htm |
| 2009-07-17 | 8-K | 2009-07-15 | 8.01 Other Events | 8.01 On July 15, 2009, Pharmacyclics, Inc. (“Pharmacyclics” or the “Company”) announced that it has set a subscription price of $1.28 per share of its common stock for its previously announced rights offering and an aggregate of approximately 18,750,000 million shares of common stock will be available for purchase in the rights offering for gross proceeds of up to approximately $24 million, less offering expenses, as provided in the prospectus. | form8k07380_07152009.htm |
| 2009-06-05 | 8-K | 2009-06-02 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On June 2, 2009, Pharmacyclics, Inc. received a confirmation from NASDAQ that its application to be transferred from the NASDAQ Global Market to the NASDAQ Capital Market had been approved. | body8k.htm |
| 2009-06-01 | 8-K | 2009-06-01 | 8.01 Other Events | 8.01 On June 1, 2009, Pharmacyclics, Inc. a Delaware corporation (the "Registrant"), announced that it filed a registration statement on Form S-3 (the "Registration Statement") with the Securities and Exchange Commission (the "SEC") for a rights offering to its existing stockholders. | body8k.htm |
| 2009-04-23 | 8-K | 2009-04-23 | 2.02 Results of Operations and Financial Condition | 2.02 On April 23, 2009, Pharmacyclics, Inc., a Delaware corporation (the "Registrant"), issued a press release regarding its financial results for its third quarter of fiscal 2009. | body8k.htm |
| 2009-04-22 | 8-K | 2009-04-16 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On April 17, 2009, the Registrant issued a press related to the matters set forth in Item 1.01. | body8k.htm |
| 2009-04-17 | 8-K | 2009-04-16 | 8.01 Other Events | 8.01 On April 16, 2009, Pharmacyclics, Inc. a Delaware corporation (the "Registrant"), announced an update to its clinical programs targeting histone deacetylase (HDAC) with its drug candidate PCI-24781 that is currently in multiple clinical trials for treating various solid and hematologic tumors. | body8k.htm |
| 2009-04-14 | 8-K | 2009-04-13 | 8.01 Other Events | 8.01 On April 13, 2009, Pharmacyclics, Inc. a Delaware corporation (the "Registrant"), announced that it has begun treating patients in a Phase 1 dose-escalation study to evaluate the safety and tolerability of PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, as a potential treatment for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). | body8k.htm |
| 2009-04-06 | 8-K | 2009-03-31 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 See the disclosure set forth under Item 1.01, which is incorporated by reference into this Item 2.03. | body8k.htm |
| 2009-03-19 | 8-K | 2009-03-16 | 8.01 Other Events | 8.01 On March 16, 2009, Pharmacyclics, Inc. (the "Company") announced that Dr. Ahmed Hamdy was hired as Chief Medical Officer of the Company. | body8k.htm |
| 2009-02-25 | 8-K | 2009-02-18 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 8.01 Other Events | 3.01 On February 18, 2009, Pharmacyclics, Inc. (the "Company") received a notice from The Nasdaq Stock Market dated February 18, 2009, about Nasdaq's equity requirements. 8.01 On February 24, 2009, the Registrant issued a press related to the matters set forth in Item 3.01. | body8k.htm |
| 2009-02-23 | 8-K | 2009-02-19 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 3.02 On February 19, 2009, Pharmacyclics, Inc. (the "Registrant") sold approximately 1.5 million shares (the "Shares") of the Registrant's common stock, par value $0.0001 per share, at $0.93 per share for an aggregate purchase price of approximately $1.4 million. 8.01 On February 20, 2009, the Registrant issued a press related to the matters set forth in Items 1.01 and 3.02. | body8k.htm |
| 2009-02-13 | 8-K | 2009-02-13 | 2.02 Results of Operations and Financial Condition | 2.02 On February 13, 2009, Pharmacyclics, Inc., a Delaware corporation (the "Registrant"), issued a press release regarding its financial results for its second quarter of fiscal 2009. | body8k.htm |
| 2009-02-13 | 8-K | 2009-02-12 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 of Certain Officers; Compensatory Arrangements of Certain Officers. | body8k.htm |
| 2009-02-11 | 8-K | 2009-02-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (c) Effective February 10, 2009, the Board of Directors (the "Board") of Pharmacylics, Inc. (the "Company") appointed Glenn C. Rice, Ph.D. as President and Chief Operating Officer of the Company. | body8k.htm |
| 2009-01-22 | 8-K | 2009-01-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective January 15, 2009, James L. Knighton resigned from his position as a member of the Board of Directors of Pharmacyclics, Inc. due to other business commitments. | body8k.htm |
| 2009-01-06 | 8-K | 2008-12-30 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On January 6, 2009, the Registrant issued a press release related to the matters set forth in Item 1.01. | body8k.htm |